immuneadher
hemagglutin
iaha
method
coronaviru
antibodi
determin
develop
diagnosi
recent
infect
detect
longpast
infect
result
compar
obtain
complement
fixat
cf
neutral
nt
indirect
hemagglutin
iha
test
iaha
method
shown
sensit
cf
nt
iha
test
detect
case
acut
infect
howev
seroepidemiolog
survey
healthi
peopl
age
iaiia
detect
antibodi
individu
nt
iha
cf
studi
preval
coronaviru
iaha
antibodi
differ
age
group
shown
second
decad
life
nearli
popul
acquir
type
antibodi
wherea
posit
end
first
decad
older
age
group
high
frequenc
c
f
antibodi
marker
recent
infect
indirectli
confirm
high
rate
reinfect
nonprotect
natur
iaha
antibodi
c
f
titer
case
correspond
iaiia
titer
howev
sera
iaha
titer
often
cfneg
recent
infect
reinfect
determin
presenc
cf
antibodi
frequent
aprilmay
octobernovemb
three
case
acut
infect
show
seroconvers
two
adult
one
child
observ
winterspr
season
iaha
appear
test
choic
seroepidemiolog
survey
epidemiolog
survey
carri
unit
state
england
brazil
indic
coronaviru
infect
worldwid
studi
preval
coronaviru
antibodi
perform
use
complement
fixat
cf
neutral
nt
l
indirect
hemagglutin
test
iha
cf
antibodi
tend
transitori
detect
within
week
month
infect
reinfect
nt
iha
antibodi
remain
elev
somewhat
longer
seem
longlast
hemagglutin
test
iaha
seroepidemiolog
survey
preval
coronaviru
antibodi
differ
age
group
diagnosi
infect
test
underli
mechan
antigen
antibodi
combin
thirdcompl
compon
c
activ
caus
agglutin
human
type
red
blood
cell
due
c
receptor
result
compar
obtain
cf
iha
nt
test
compar
test
iaha
method
appear
superior
detect
remot
infect
appear
method
choic
seroepidemiolog
survey
present
report
describ
develop
use
immuneadher
coronaviru
refer
strain
kindli
suppli
dr
hs
kay
virolog
respiratori
unit
center
diseas
control
atlanta
georgia
grown
strain
diploid
human
fetal
lung
fibroblast
viral
infect
assay
well
cell
titer
calcul
method
reed
muench
lo
three
group
sera
examin
sera
healthi
individu
studi
preval
antibodi
coronaviru
differ
age
group
b
two
group
sera
adult
year
first
taken
octobernovemb
second
aprilmay
investig
incid
coronaviru
infect
reinfect
two
differ
period
year
pair
sera
c
pair
sera
infant
month
admit
hospit
acut
respiratori
infect
determin
etiolog
role
coronaviru
respect
pathogenesi
sever
respiratori
tract
infect
infanc
refer
guinea
pig
immun
serum
serolog
method
kindli
suppli
dr
hs
kay
human
embryo
fibroblast
cell
cultur
grown
flask
eagl
minimum
essenti
medium
mem
supplement
fetal
calf
serum
cell
monolay
complet
cell
inocul
coronaviru
multipl
infect
moi
follow
incub
minut
cell
cultur
fed
eagl
mem
contain
fetal
calf
serum
incub
continu
cytopath
effect
cell
wash
three
time
hank
balanc
salt
solut
bss
final
ml
hank
bss
ad
flask
cell
frozen
thaw
content
flask
pool
centrifug
rpm
minut
supernat
contain
antigen
collect
store
antigen
use
iha
iaha
test
cf
antigen
prepar
cell
cultur
method
hamr
procknow
iaha
test
perform
follow
serial
twofold
dilut
serum
made
triplic
use
gelatin
veron
buffer
gvb
diluent
tissu
cultur
grade
microtit
v
plate
sterilin
teddington
middlesex
uk
ml
well
antigen
ad
first
control
antigen
second
gvb
third
set
serum
dilut
ml
follow
incub
one
hour
optim
dilut
guinea
pig
complement
c
gvb
ml
ad
well
plate
incub
minut
dithiothreitol
dtt
concentr
mgml
edtagvb
two
part
edta
ph
ad
three
part
gvb
ad
ml
final
suspens
human
type
red
blood
cell
rbc
gvb
ml
ad
well
micropl
left
room
temperatur
minut
hemagglutin
pattern
read
observ
pattern
rang
reaction
nonagglutin
cell
neg
reaction
reaction
partial
complet
agglutin
cell
posit
reaction
lbcf
procedur
c
microbiolog
assoc
bethesda
maryland
titer
accord
procedur
dilut
use
gvb
optim
dilut
c
cf
iaha
test
ident
human
type
rbc
obtain
suitabl
donor
whole
blood
collect
twice
volum
alsev
solut
store
week
prior
use
rbc
wash
gvb
adjust
suspens
gvb
antigen
control
antigen
hour
night
centrifug
ooog
minut
supernat
test
iaha
reactiv
specif
antibodi
titer
complet
abolish
control
specif
serum
contain
specif
antibodi
absorb
cf
antigen
prepar
cell
method
hamr
procknow
cf
test
perform
accord
lbcf
procedur
l
neutral
antibodi
measur
micropl
cell
monolay
six
set
twofold
dilut
heatinactiv
serum
minut
made
medium
supplement
fetal
calf
serum
mlwell
mix
equal
volum
viru
dilut
give
tissu
cultur
infect
dose
tcidso
per
ml
incub
one
hour
cell
suspens
contain
x
cell
per
millilit
ad
ml
well
micropl
incub
day
viru
control
amount
viru
detect
microscop
observ
includ
rang
micropl
cell
monolay
fix
stain
crystal
violet
appropri
serum
lo
dilut
cell
control
includ
test
serum
titer
calcul
method
reed
muench
iha
test
perform
accord
method
report
kay
ong
dowdl
use
either
fresh
glutaraldehydefix
sheep
erythrocyt
accord
procedur
describ
iha
test
appli
human
cytomegaloviru
human
herpesviru
antibodi
determin
sheep
cell
agglutinin
elimin
absorpt
sera
tan
sheep
erythrocyt
water
bath
minut
specif
iha
test
determin
indirect
hemagglutin
inhibit
specif
iaha
method
test
use
refer
guinea
pig
immun
serum
preimmun
serum
use
neg
three
infant
month
old
posit
one
child
two
adult
human
sera
recent
infect
sera
well
character
cf
iha
nt
use
block
test
antigen
block
iaha
reaction
posit
sera
wherea
control
antigen
comparison
iaha
iha
nt
cf
test
detect
antibodi
made
human
sera
drawn
healthi
peopl
differ
age
fig
tabl
sera
test
posit
iaha
test
iahaposit
sera
thirti
show
cf
titer
iha
titer
nt
titer
titer
detect
sera
test
shown
figur
antibodi
would
detect
mani
sera
test
nt
iha
two
test
agre
posit
sera
iha
ad
eight
posit
result
alreadi
detect
nt
cf
antibodi
alway
detect
also
iaha
nt
iha
test
report
tabl
antibodi
detect
infant
month
test
antibodi
start
appear
group
month
year
increas
frequenc
group
preval
antibodi
determin
four
test
show
larg
variat
among
older
age
group
titer
consist
found
less
case
cf
test
iaha
iha
nt
test
show
intermedi
valu
sinc
well
known
highest
frequenc
infect
take
place
winterspr
season
compar
group
sera
drawn
healthi
adult
octobernovemb
group
sera
taken
aprilmay
ofthes
pair
sera
result
report
tabl
show
percentag
sera
show
cf
antibodi
octobernovemb
group
wherea
aprilmay
group
sera
show
presenc
antibodi
frequenc
close
iaha
furthermor
octobernovemb
group
go
correspond
iaha
titer
fig
howev
sera
iaha
titer
cfneg
case
pair
sera
two
show
seroconvers
four
test
tabl
case
acut
upper
lower
respiratori
tract
infect
children
month
antibodi
determin
four
method
acut
convalesc
sera
one
case
show
seroconvers
report
tabl
clinic
symptom
fever
cough
otiti
possibl
etiolog
agent
viral
bacteri
rule
iaha
test
describ
present
report
appear
reliabl
serolog
test
determin
coronaviru
antibodi
seroepidemiolog
survey
technic
problem
nonspecif
hemagglutin
may
sometim
aris
contamin
sera
frozen
sera
store
long
time
howev
usual
easi
distinguish
fine
granular
hemagglutin
pattern
due
specif
antigenantibodi
reaction
fuzzi
pattern
due
nonspecif
reaction
far
extens
epidemiolog
survey
carri
use
cf
iha
nt
test
cf
test
employ
rel
low
level
seroposit
found
popul
sampl
differ
countri
level
seroposit
reach
higher
valu
potent
antigen
prepar
use
special
concentr
procedur
iha
nt
test
report
good
agreement
sera
test
determin
antibodi
result
appar
show
nt
test
sensit
iha
reason
discrep
may
low
initi
dilut
accur
test
perform
micropl
tube
howev
result
show
iaha
test
far
sensit
iha
nt
test
detect
longlast
antibodi
ferent
age
group
appear
coronaviru
infect
start
occur
first
five
year
life
adult
show
presenc
antibodi
coronaviru
serum
parallel
cf
antibodi
marker
recent
infect
present
remark
variat
frequenc
distribut
second
decad
life
data
indirectli
confirm
high
rate
coronaviru
reinfect
report
previous
regard
point
particular
neither
iha
neutral
antibodi
shown
protect
reinfect
describ
carrier
type
antibodi
basi
result
conclud
even
iaha
antibodi
protect
whether
immun
statu
coronaviru
depend
presenc
specif
secretori
iga
cellmedi
immun
still
determin
far
season
distribut
coronaviru
infect
concern
result
show
coronaviru
infect
occur
frequent
itali
winterspr
period
agre
data
previous
report
countri
studi
use
paramet
recent
infect
titer
cf
antibodi
found
almost
three
time
frequenc
cf
antibodi
spring
compar
fall
season
titer
use
paramet
frequenc
cf
antibodi
spring
drop
less
doubl
furthermor
cf
titer
look
preval
antibodi
detect
iaha
test
difwer
often
difficult
read
incomplet
complement
fixat
far
epidemiolog
technic
data
suggest
perform
cf
test
start
dilut
could
mislead
diagnosi
recent
infect
howev
cf
titer
alway
agreement
iaha
titer
testifi
specif
reaction
opinion
cf
titer
may
longer
last
higher
titer
interpret
seem
agre
result
bradburn
somerset
show
high
preval
cf
antibodi
potent
antigen
employ
cf
test
employ
studi
use
diagnosi
recent
infect
reinfect
use
cf
test
singl
serum
sampl
suffici
diagnosi
recent
infect
howev
seroepidemiolog
survey
new
iaha
test
appear
greatli
superior
test
avail
iha
nt
conclus
pair
acut
convalesc
sera
avail
four
test
